中文Laos Vientiane-January 03, 2024-BigBear Pharma, a leading alchemon company focusing on development and commercial cancer innovation therapy, announced today that two products has been approved by the Ministry of Health of Laos.
The approved drugs are:
Trelagliptin: Sell with the TEGLIDX brand name. Trelagliptin was approved for marketing in Japan on March 26, 2015. It is an ultra-long-acting dipeptidyl peptidase IV (DPP-4) inhibitor that can effectively control blood sugar by taking one pill per week.
Ivosidenib: Sell with the AIVODX brand name. Ivosidenib is the world’s first approved IDH1 inhibitor. In July 2018, Ivosidenib was approved by the US FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) carrying IDH1 mutations. In August 2021, Ivosidenib was approved by the US FDA for the treatment of adult patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) carrying IDH1 mutations.
About BigBear Pharmaceuticals:
BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.
Forward-Looking Statements:
Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.